株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌幹細胞治療薬の世界市場:2019年~2023年

Global Cancer Stem Cell Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 865028
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.90円で換算しております。
Back to Top
癌幹細胞治療薬の世界市場:2019年~2023年 Global Cancer Stem Cell Therapeutics Market 2019-2023
出版日: 2019年05月29日 ページ情報: 英文 104 Pages
概要

癌は世界中で最も一般的な死因の一つです。乳癌、膀胱癌、肺癌、白血病、膵臓癌、前立腺癌など、様々な種類の癌の罹患率が高いため、世界中で死亡率が上昇しています。ハンガリー、オランダ、デンマーク、クロアチアなどの国では、過去数年間で癌の症例が増加しています。世界中で癌関連罹患率が増加していることによって、癌幹細胞治療薬の需要が促進される見込みです。世界の癌幹細胞治療薬市場は予測期間中に11%以上のCAGRで成長する見通しです。

当レポートでは、世界の癌幹細胞治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別
  • タイプ別比較:市場規模および予測(2018年~2023年)
  • 同種幹細胞移植
  • 自家幹細胞移植
  • 市場機会:タイプ別

第7章 顧客情勢

第8章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 癌幹細胞の重要なシグナル伝達経路に関する研究活動の増加
  • 癌幹細胞の同定における幹細胞マーカーの有用性
  • 人工多能性幹細胞(iPS細胞)を用いたファーストインクラス治療薬の開発

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Cellerant Therapeutics, Inc.
  • Celularity Inc.
  • Gamida Cell Ltd.
  • Nohla Therapeutics, Inc.
  • 大日本住友製薬

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

図表
  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Type - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by type
  • Exhibit 19: Allogeneic stem cell transplant - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Allogeneic stem cell transplant - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Allogeneic stem cell transplants under development
  • Exhibit 22: Autologous stem cell transplant - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Autologous stem cell transplant - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Late-stage cancer stem cell therapy
  • Exhibit 39: Impact of drivers and challenges
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: Cellerant Therapeutics Inc. - Vendor overview
  • Exhibit 46: Cellerant Therapeutics Inc. - Key offerings
  • Exhibit 47: Celularity Inc. - Vendor overview
  • Exhibit 48: Celularity Inc. - Key offerings
  • Exhibit 49: Gamida Cell Ltd. - Vendor overview
  • Exhibit 50: Gamida Cell Ltd. - Business segments
  • Exhibit 51: Gamida Cell Ltd. - Key offerings
  • Exhibit 52: Nohla Therapeutics Inc. - Vendor overview
  • Exhibit 53: Nohla Therapeutics Inc. - Key offerings
  • Exhibit 54: Sumitomo Dainippon Pharma Co. Ltd. - Vendor overview
  • Exhibit 55: Sumitomo Dainippon Pharma Co. Ltd. - Business segments
  • Exhibit 56: Sumitomo Dainippon Pharma Co. Ltd. - Organizational developments
  • Exhibit 57: Sumitomo Dainippon Pharma Co. Ltd. - Segment focus
  • Exhibit 58: Sumitomo Dainippon Pharma Co. Ltd. - Key offerings
  • Exhibit 59: Validation techniques employed for market sizing
  • Exhibit 60: Definition of market positioning of vendors
目次
Product Code: IRTNTR31416

About this market

Cancer is one of the most common causes of deaths across the world. The high prevalence of various types of cancer, such as breast cancer, bladder cancer, lung cancer, leukemia, pancreatic cancer, and prostate cancer, has increased the mortality rate across the world. Countries such as Hungary, Netherlands, Denmark, and Croatia have witnessed an increase in the number of cancer cases over the past few years. The growing instances of cancer-related morbidity across the world will fuel the demand for cancer stem cell therapeutics and drive the growth of the global cancer stem cell therapy market size at a CAGR of over 11% during the forecast period.

Market Overview

Strong drug pipeline

The prevalence of cancer across the world is driving many vendors in the market to develop novel stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, CanStem 303C is an orally administered drug developed to inhibit cancer cell pathways in patients with metastatic pancreatic ductal adenocarcinoma. The drug is currently in Phase III of clinical trials and is expected to be launched in the US by 2021.

Side-effects of stem cell transplant

Stem cell transplant causes several immediate side effects such as fatigue, vomiting, low levels of platelets and red blood cells, and diarrhea. It may also cause several long term effects such as infertility, eye disorders, early menopause, lung and bone damage, and risk of developing other cancer types. These risk factors may hinder the growth of the global cancer stem cell therapy market size.

For the detailed list of factors that will drive and challenge the growth of the cancer stem cell therapy market size during 2019-2023.

Competitive Landscape

The market appears to be fairly concentrated with few players occupying the market share. Companies such as Cellerant Therapeutics Inc. and Celularity Inc. have intensified competition. Factors such as the rising prevalence of cancer and the strong drug pipeline will provide significant growth opportunities for cancer stem cell therapy companies. Cellerant Therapeutics Inc., Celularity Inc., Gamida Cell Ltd., Nohla Therapeutics Inc., and Sumitomo Dainippon Pharma Co. Ltd. are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Allogeneic stem cell transplant - Market size and forecast 2018-2023
  • Autologous stem cell transplant - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research activity on cancer stem cell key signaling pathways
  • Availability of stem cell markers in the identification of cancer stem cells
  • Development of first-in-class therapeutics using induced pluripotent stem cells

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Cellerant Therapeutics, Inc.
  • Celularity Inc.
  • Gamida Cell Ltd.
  • Nohla Therapeutics, Inc.
  • Sumitomo Dainippon Pharma Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Back to Top